• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·ENDY.TA
Share

Endymed Ltd Stocks

ILA 320.1Last Updated 16.02.2025

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

ILA 140527.41758

ILA 320.1
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Endymed Ltd, a medical technology company, designs, develops, and commercializes energy based medical aesthetic treatment systems for the professional and consumer markets worldwide. Its products comprise EndyMed PRO, a multi-application treatment platform; PURE 2.0 that offers professional skin tightening, body contouring, and functional resurfacing; and 3DEEP radiofrequency technology, a solution for the treatment of skin tightening, wrinkle reduction, body contouring, texture enhancement, cellulite reduction, circumferential reduction, acne and acne scar reduction, stretch mark reduction, RF micro needling, and fractional resurfacing. The company was founded in 2007 and is based in Freehold, New Jersey.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

07.08.2026 17:41

The number of jobs in the U.S. fell in July, contrary to market expectations. What will happen to interest rates?

07.08.2026 17:27

Investor optimism is at its highest level since 2021. Here’s BofA’s advice for protecting your portfolio

07.08.2026 16:46

Papa John's stock has plummeted to a 14-year low. Why are investors selling it off?

07.08.2026 16:09

Iran's chief negotiator accused Trump of "theatrical diplomacy"

07.08.2026 15:30

From Antarctica to the Nasdaq: How Lindblad Expeditions Made a Fortune from a Love of the Wild

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026